Procter & Gamble (NYSE: PG) opened fiscal 2027 with a clean beat. Revenue hit $23.3 billion against a $22.8 billion consensus. Core EPS reached $2.00, well clear of the $1.88 expected. Organic sales rose 4% on 2% volume and favorable mix, with Beauty and Fabric & Home Care each posting 5% organic gains. The headline numbers look fine for a consumer staple.
But the quarter's real story sits in the margin structure. Core gross margin fell 150 basis points to 50.0%, the company's lowest first-quarter level in at least three years. The culprit: $1.4 billion in commodity costs, product reinvestments, and unfavorable mix more than swallowed 250 basis points of productivity savings. P&G's gross productivity engine is running at full throttle. It is still losing ground.
Management called the quarter a "solid start" that keeps the company on track. That guidance, however, was unchanged on earnings despite the beat. Core EPS growth remains pegged at 0% to 3%, or $6.89 to $7.11, with a $0.79 per share drag from commodities, interest, and FX. The all-in sales guidance was raised to +2% to +4% to reflect the Thorne acquisition, but organic sales growth stayed at +1% to +3%. The beat does not change the math for the rest of the year.
P&G returned $3.9 billion to shareholders in the quarter through dividends and buybacks, and reaffirmed plans to return over $10 billion in dividends and roughly $5 billion in buybacks for the full year. Yet the buyback pace is slowing. P&G repurchased $1.3 billion in Q1, down from $1.5 billion in the year-ago period, and diluted share count fell just 1.2% year over year. Free cash flow productivity hit 93%. The tempered buyback suggests management is conserving optionality against that $0.79 per share headwind.
Segment performance was uneven beneath the aggregate. Fabric & Home Care, P&G's largest segment, delivered 5% organic growth on 4% volume gains in North America and Europe. Baby, Feminine & Family Care managed only 3% organic growth, with Baby Care's mid-single-digit volume increase partially offset by lower pricing in North America. Health Care saw organic sales rise just 3%, with volume declining 3% as Oral Care and Personal Health Care both posted unit volume drops. P&G is gaining share in some categories while losing shelf space in others.
The margin compression looks structural for the current fiscal year. Commodity costs are not a one-quarter phenomenon; the company now expects a $1.4 billion after-tax headwind for the full year, up from whatever was embedded in the initial outlook. Core gross margin has now declined year over year for three consecutive quarters. Until commodity costs stabilize or pricing accelerates, P&G's earnings growth will remain constrained to the low single digits regardless of how many beats it posts.
The trajectory of commodity costs and P&G's ability to push through additional pricing without sacrificing volume now matter most. Pricing contribution was just 0.4% in Q1, the lowest in recent memory. If input cost inflation persists, P&G may need to choose between margin and market share. The stock gets a solid quarter and a cautious outlook. The guidance said as much.